Skip to main content

In FY 02, Applera s White Pocketed $7.9M; Celera s Ordoez Paid $1.6M; ABI s Hunkapiller Took Home $1.3M

A note to readers: This is the first of a new breed of briefs GenomeWeb will cover. Called Proxy Reports, these briefs will review annual proxy statements issued to the US Securities and Exchange Commission by Genome Technology Index companies.


NEW YORK, Sept. 16 - Applera's three top executives were paid $5 million in salaries, bonuses, and near-term stock options last year, recent filings with the federal securities agency show.


However, exercised stock options, dividends, and perks took that figure significantly higher.


For the fiscal year ended June 2002, Applera CEO Tony White earned a total of $2.4 million, including $1 million in salary, a full bonus of $1.15 million, vested performance units worth $125,000, and perks and dividends totaling $192,044, including personal use of company aircraft worth $155, 012.


He also realized $5.5 million in stock-option gains on Celera and Applera stock, bringing his total compensation to $7.9 million.


White also received options to buy 255,000 shares of Applera-Applied Biosystems and 85,000 shares of Celera-Applied Biosystems, a package estimated to be worth between $5.6 million and $14.3 million by 2012.


Last year, White was paid $25.8 million, including a $24 million restricted stock award, and drew total compensation of $61.9 million, thanks to $27.2 million in stock option gains.


New Celera Diagnostics and Celera Genomics President Kathy Ordoñez came in at $1.6 million, including $374,424 in salary, $420,325 in bonuses, and 40,000 shares of restricted Applera-Celera stock now worth $774,800 that vest over the next three years.


Ordoñez was also awarded options on 85,000 shares of Applera-ABI and 128,000 shares of Celera-ABI that vest fully by 2012. Her package is potentially worth between $2.6 million and $6.7 million.


In the fiscal year ending June 2002, senior vice president Michael Hunkapiller pulled down roughly $1 million, including $529,307 in salary and $462,977 in bonuses, $2,125 in dividends, and payments from vested performance units worth $62,500.


Hunkapiller also realized $253,364 in stock-option gains. He was awarded 141,000 options on shares of Applera-ABI and 34,000 shares of Celera-ABI, estimated to be worth $2.4 million and $6 million by 2012.


For further information, see the company proxy report.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.